[
    [
        {
            "time": "2021-07-15",
            "original_text": "华熙生物中期营收预增超95%，玻尿酸巨头多元化拓新成趋势",
            "features": {
                "keywords": [
                    "华熙生物",
                    "营收预增",
                    "玻尿酸",
                    "多元化"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美",
                    "护肤"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华熙生物中期营收预增超95%，玻尿酸巨头多元化拓新成趋势",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-01",
            "original_text": "上半年净利润预增超30%，华熙生物总市值超1300亿",
            "features": {
                "keywords": [
                    "华熙生物",
                    "净利润",
                    "市值"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上半年净利润预增超30%，华熙生物总市值超1300亿",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-20",
            "original_text": "华西证券首予华熙生物买入评级，医美系列产品报告之四：医美产品2021年有望迎来快速放量，功能护肤品持续驱动公司高速增长",
            "features": {
                "keywords": [
                    "华西证券",
                    "买入评级",
                    "医美产品",
                    "功能护肤品"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美",
                    "护肤"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华西证券首予华熙生物买入评级，医美系列产品报告之四：医美产品2021年有望迎来快速放量，功能护肤品持续驱动公司高速增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-25",
            "original_text": "业绩快报 | 业绩超预期股价爆雷，华熙生物大跌7%，千亿市值龙头难坐稳？",
            "features": {
                "keywords": [
                    "业绩超预期",
                    "股价爆雷",
                    "大跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "业绩快报 | 业绩超预期股价爆雷，华熙生物大跌7%，千亿市值龙头难坐稳？",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-10",
            "original_text": "光大证券：华熙生物（688363.SH）上半年收入翻番、归母净利润增长超过30%，维持“买入”评级",
            "features": {
                "keywords": [
                    "光大证券",
                    "买入评级",
                    "净利润增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "光大证券：华熙生物（688363.SH）上半年收入翻番、归母净利润增长超过30%，维持“买入”评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-30",
            "original_text": "华西证券：华熙生物（688363.SH）全球HA原料供应商龙头，首予“买入”评级",
            "features": {
                "keywords": [
                    "华西证券",
                    "买入评级",
                    "HA原料供应商"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华西证券：华熙生物（688363.SH）全球HA原料供应商龙头，首予“买入”评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-07-18",
            "original_text": "每日“药”闻|华熙生物半年利润预增30%-40%，不及营收增幅；百利药业四抗获批临床",
            "features": {
                "keywords": [
                    "华熙生物",
                    "半年利润",
                    "预增"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "每日“药”闻|华熙生物半年利润预增30%-40%，不及营收增幅；百利药业四抗获批临床",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-05",
            "original_text": "华熙生物大跌6%，机构：第二季度业绩超预期",
            "features": {
                "keywords": [
                    "华熙生物",
                    "大跌",
                    "第二季度业绩"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华熙生物大跌6%，机构：第二季度业绩超预期",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]